Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 3/20 | 0.43 |
| ▸ | HCRTR1 known ✓ | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 known ✓ | O43614 | 1/20 | 0.35 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.34 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242465 | 0.78 | PDE5A (0.49) | PDE5APTGER1ALDH1A1HPGDCYP2C9 | |
| SCHEMBL14290109 | 0.78 | PDE5A (0.66) | PDE5APTGER1ALDH1A1HPGDCYP2C9 | |
| SCHEMBL1900992 | 0.68 | PDE5A (0.70) | PDE5AALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL9278722 | 0.68 | PDE5A (0.62) | PDE5APKMALDH1A1HPGDCYP2C9 | |
| SCHEMBL3246620 | 0.66 | PDE5A (0.54) | PDE5AALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL3244030 | 0.65 | PDE5A (0.46) | PDE5AALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL14696455 | 0.64 | PKM (0.41) | PKMSLC6A7TAS2R14HCRTR1HCRTR2 | |
| SCHEMBL3205814 | 0.63 | PDE5A (0.64) | PDE5AALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL3243388 | 0.61 | PDE5A (0.71) | PDE5AALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL3073752 | 0.61 | PDE5A (0.73) | PDE5AALDH1A1HPGDCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418176-B1 | Pyrazole derivates, their preparation and their use in drugs | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-7300950-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2005-08-11 | — | — | US | disclosed |
| US-6897232-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1418176-A1 | Pyrazole derivates, their preparation and their use in drugs | Aventis Pharma Deutschland GmbH (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-0908456-B1 | Pyrazole derivatives, their preparation and their use in drugs | AVENTIS PHARMA GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-06-05 | — | — | US | disclosed |
| US-6162819-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| CN-1214339-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-04-21 | — | — | CN | disclosed |
| EP-0908456-A1 | Pyrazole derivatives, their preparation and their use in drugs | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3A, PDE3B, PDE5A | PDE5A 3/4885HCRTR1 3133/4885HCRTR2 4057/4885 |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3B, PDE3A, PDE5A | PDE5A 3/4885HCRTR1 3437/4885HCRTR2 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.